ClinVar Miner

Submissions for variant NM_058216.3(RAD51C):c.672_705+65dup

dbSNP: rs1555597214
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV000216680 SCV000276212 likely benign Hereditary cancer-predisposing syndrome 2021-05-05 criteria provided, single submitter clinical testing This alteration is classified as likely benign based on a combination of the following: population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity.
Invitae RCV000532240 SCV000650021 uncertain significance Fanconi anemia complementation group O 2021-08-12 criteria provided, single submitter clinical testing
Color Diagnostics, LLC DBA Color Health RCV000216680 SCV001340508 uncertain significance Hereditary cancer-predisposing syndrome 2022-01-27 criteria provided, single submitter clinical testing This variant causes a duplication of the 3' end of exon 4 and the 5' end of intron 4 of the RAD51C gene. This variant creates a duplicate copy of the intron 4 splice donor site, however, the splicing impact if any has not been functionally tested. To our knowledge, functional studies have not been performed for this variant. This variant has not been reported in individuals affected with hereditary cancer in the literature. This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance.
GenomeConnect - Invitae Patient Insights Network RCV001535621 SCV001749647 not provided Breast-ovarian cancer, familial, susceptibility to, 3; Fanconi anemia complementation group O no assertion provided phenotyping only Variant interpreted as Uncertain significance and reported on 06-12-2017 by Invitae. GenomeConnect-Invitae Patient Insights Network assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. Registry team members make no attempt to reinterpret the clinical significance of the variant. Phenotypic details are available under supporting information.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.